Do disasters predict international pharmacy legislation?


Journal

Australian health review : a publication of the Australian Hospital Association
ISSN: 1449-8944
Titre abrégé: Aust Health Rev
Pays: Australia
ID NLM: 8214381

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 18 04 2019
accepted: 04 09 2019
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 24 3 2021
Statut: ppublish

Résumé

Objective The aim of this study was to explore whether a relationship exists between the number of disasters a jurisdiction has experienced and the presence of disaster-specific pharmacy legislation. Methods Pharmacy legislation specific to disasters was reviewed for five countries: Australia, Canada, UK, US and New Zealand. A binary logistic regression test using a generalised estimating equation was used to examine the association between the number of disasters experienced by a state, province, territory or country and whether they had disaster-specific pharmacy legislation. Results Three of six models were statistically significant, suggesting that the odds of a jurisdiction having disaster-specific pharmacy legislation increased as the number of disasters increased for the period 2007-17 and 2013-17. There was an association between the everyday emergency supply legislation and the presence of the extended disaster-specific emergency supply legislation . Conclusions It is evident from this review that there are inconsistencies as to the level of assistance pharmacists can provide during times of crisis depending on their jurisdiction and location of practice. It is not a question of whether pharmacists have the skills and capabilities to assist, but rather what legislative barriers are preventing them from being able to contribute further to the disaster healthcare team. What is known about the topic? The contributing factors to disaster-specific pharmacy legislation has not previously been explored in Australia. It can be postulated that the number of disasters experienced by a jurisdiction increases the likelihood of governments introducing disaster-specific pharmacy legislation based on other countries. What does this paper add? This study compared five countries and their pharmacy legislation specific to disasters. It identified that as the number of disasters increases, the odds of a jurisdiction having disaster-specific emergency supply or disaster relocation or mobile pharmacy legislation increases. However, this is likely to be only one of many factors affecting the political decisions of when and what legislation is passed in relation to pharmacists' roles in disasters. What are the implications for practitioners? Pharmacists are well situated in the community to be of assistance during disasters. However, their ability to help patients with chronic disease management or providing necessary vaccinations in disasters is limited by the legislation in their jurisdiction. Releasing pharmacists' full potential in disasters could alleviate the burden of low-acuity patients on other healthcare services. This could subsequently free up other healthcare professionals to treat high-acuity patients and emergencies.

Identifiants

pubmed: 32492363
pii: AH19093
doi: 10.1071/AH19093
doi:

Substances chimiques

Prescription Drugs 0

Types de publication

Comparative Study Journal Article

Langues

eng

Pagination

392-398

Auteurs

Kaitlyn E Watson (KE)

School of Clinical Sciences, Queensland University of Technology, Brisbane, Qld 4000, Australia. Email: judith.singleton@qut.edu.au; vivienne.tippett@qut.edu.au; l.nissen@qut.edu.au; and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Qld 4059, Australia; and Corresponding author. Email: kewatson@ualberta.ca.

Judith A Singleton (JA)

School of Clinical Sciences, Queensland University of Technology, Brisbane, Qld 4000, Australia. Email: judith.singleton@qut.edu.au; vivienne.tippett@qut.edu.au; l.nissen@qut.edu.au; and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Qld 4059, Australia.

Vivienne Tippett (V)

School of Clinical Sciences, Queensland University of Technology, Brisbane, Qld 4000, Australia. Email: judith.singleton@qut.edu.au; vivienne.tippett@qut.edu.au; l.nissen@qut.edu.au; and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Qld 4059, Australia.

Lisa M Nissen (LM)

School of Clinical Sciences, Queensland University of Technology, Brisbane, Qld 4000, Australia. Email: judith.singleton@qut.edu.au; vivienne.tippett@qut.edu.au; l.nissen@qut.edu.au; and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Qld 4059, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH